Does Ribociclib Interact with Sensitive Cyp3a Substrates?
Ribociclib and Sensitive Cyp3a Substrates have a moderate drug interaction according to U.S. FDA drug labeling data. KISQALI increases exposure of CYP3A4 substrates. Monitor for increased adverse reactions and consider dose reduction of the CYP3A substrate. The mechanism involves kisqali inhibits cyp3a4, increasing substrate exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Ribociclib and Sensitive Cyp3a Substrates occurs because kisqali inhibits cyp3a4, increasing substrate exposure. Clinically, this means kisqali increases exposure of cyp3a4 substrates. monitor for increased adverse reactions and consider dose reduction of the cyp3a substrate. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Ribociclib and your doctor is considering prescribing Sensitive Cyp3a Substrates (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider